| CRISPR Therapeutics–SEVERAL: investment, 201809 public offering $200m net $185.7m with 4.21m common shares at $46.5/share |
2018-09-19 |
| BluCon Biotech–BRAIN: industrial biotechnology, 201809– strategic research collab microbial strain developm for PLA-based bioplastic |
2018-09-18 |
| GeNeuro–Servier: investment, 201809 existent investor Servier |
2018-09-18 |
| Almirall–Evotec: drug discovery services, 201809– collab r+d therapies for dermatological diseases |
2018-09-17 |
| BioPhero–SEVERAL: investment, 201809 seed financing round €3m from Novo Seeds + Syngenta Ventures + Syddansk Innovation |
2018-09-17 |
| Iowa State Univ–Thermo Fisher: mass spectrometry, 201809 supply existent early user of new VetDrugs Explorer Collection LC-MS/MS solution |
2018-09-17 |
| Luciole Medical–SEVERAL: investment, 201809 financing round Series A CHF5.3m (€4.7m) led by SVC Ltd (CreditSuisse) |
2018-09-17 |
| NeuMoDx–Qiagen: investment, 201809 existent Qiagen owns 19.9% of NeuMoDx |
2018-09-17 |
| NeuMoDx–Qiagen: investment, 201809– option to acquire remaining 80.1% of NeuMoDx for $234m |
2018-09-17 |
| Qiagen–NeuMoDx: molecular diagnostics, 201809– collab distribution outside US by Qiagen + implementation of Qiagen reagents on NeuMoDex PRC systems |
2018-09-17 |
| Coda Biotherapeutics–SEVERAL: investment, 201809 financing round Series A $19m co-led by MPM Capital + Versant Ventures |
2018-09-12 |
| Merck (DE)–AstraZeneca: digital pathology, 201809– collab multi-year partnership with Definiens using TissuePhenomics for biomarker quantification |
2018-09-10 |
| RSP Systems–SEVERAL: investment, 201809 financing round Series B 2nd closing €3.85m incl new investor Trumpf Venture GmbH |
2018-09-10 |
| RSP Systems–Trumpf: investment, 201809 financing round Series B 2nd closing totalling €3.85m incl new investor Trumpf Venture GmbH |
2018-09-10 |
| Menarini–Lunaphore: staining technology, 201809– collab Menarini Diagnostics to market LabSat Frozen tissue staining solution |
2018-09-09 |
| Celgene–Evotec: drug discovery services, 201809– strategic RnD collab in field of targeted protein degradation using Panomics platform |
2018-09-06 |
| Novartis–Aurobindo: investment, 201809 acquisition $900m cash + $100m milestones of Sandoz US dermatology + oral generics businesses by Aurobindo USA |
2018-09-06 |
| Polyphor–Novo Group: investment, 201809 capital increase CHF6.8m with 179k shares at CHF38/share sold to Novo REPAIR Impact Fund |
2018-09-06 |
| Polyphor–Novo Group: investment, 201809– project-based + royalty-bearing investment up to CHF4.7m based on milestones in OMPTA program by Novo REPAIR |
2018-09-06 |
| Twentyeight-Seven–Astellas: investment, 201809 financing round Series A totalling $65m incl co-investor Astellas Venture Management |
2018-09-06 |
| Twentyeight-Seven–JnJ: investment, 201809 financing round Series A totalling $65m incl co-investor JnJ Innovation JJDC Inc |
2018-09-06 |
| Twentyeight-Seven–Longwood Fund: investment, 201809 financing round Series A totalling $65m incl co-investor Longwood Fund |
2018-09-06 |
| Twentyeight-Seven–MPM Capital: investment, 201809 financing round Series A totalling $65m incl founding + co-lead investor MPM Capital |
2018-09-06 |
| Twentyeight-Seven–Novartis: investment, 201809 financing round Series A totalling $65m incl co-lead investor NVF |
2018-09-06 |
| Twentyeight-Seven–SEVERAL: investment, 201809 financing round Series A $65m co-led by founding investor MPM Capital + NVF |
2018-09-06 |
| Twentyeight-Seven–Temasek: investment, 201809 financing round Series A totalling $65m incl co-investor Vertex Ventures HC |
2018-09-06 |
| Creoptix–Waters: investment, 201809 investment by new investor Waters Corp |
2018-09-05 |
| Miracor–SEVERAL: investment, 201809 financing round Series D totalling €30m final closing led by Ming Capital (CN) |
2018-09-04 |
| Mologen–SEVERAL: investment, 201809 capital increase €8.2m with 1.73m new shares at €4.7/share to existing + new investors |
2018-09-03 |
| CHDI–Evotec: drug discovery services, 201808–2023 collab service extension CDHI funding up to 75 full-time scientists for Huntington’s disease drugs |
2018-08-30 |
| Lunaphore–SEVERAL: investment, 201808 financing round Series B CHF5.3m from existing + new investors |
2018-08-30 |
| Nebula Genomics–Heartbeat Labs: investment, 201808 seed financing round totalling $4.3m incl Heartbeat Labs |
2018-08-29 |
| Nebula Genomics–SEVERAL: investment, 201808 seed financing round $4.3m from ten leading tech + biotech VCs |
2018-08-29 |
| PhagoMed–Austria (govt): grant, 201808–2021 research project grant €3.5m from FFG |
2018-08-28 |
| PhagoMed–Austria (govt): investment, 201808 seed financing round totalling €1.55m incl €800k aws-Seedfinancing |
2018-08-28 |
| PhagoMed–OTHER: investment, 201808 seed financing round totalling €1.55m incl €750k from private investors |
2018-08-28 |
| PhagoMed–SEVERAL: investment, 201808 seed financing round €1.55m from private investors + aws |
2018-08-28 |
| Evotec–Centogene: drug discovery, 201808– collab ww strategic €na discovery + developm of treatments for rare genetic diseases |
2018-08-27 |
| Proteomedix–Altos Venture: investment, 201808 financing round totalling CHF5.2m incl exising + lead investor Altos Venture |
2018-08-27 |
| Proteomedix–SEVERAL: investment, 201808 financing round CHF5.2m from exising investors led by Altos Venture + incl ZKB |
2018-08-27 |
| Proteomedix–Zürcher Kantonalbank: investment, 201808 financing round totalling CHF5.2m incl exising + co-investor ZKB |
2018-08-27 |
| Roche–Affimed: antibody cancer drug, 201808– collab $96m ufpront + $5b milestones + royalties using ROCK platform to develop ABs with Genentech |
2018-08-27 |
| Thermo Fisher–BioStrata: public relations, 201808 service existent by BioStrata |
2018-08-27 |
| Univ Wisconsin–Thermo Fisher: FAIMS technology, 201808 supply use of FAIMS device for shotgun proteomics by Joshua Coon |
2018-08-27 |
| Hain Lifescience–Bruker: investment, 201808– acquisition €na of 80% majority interest with option to acquire rest in 2012 ANNOUNCED |
2018-08-24 |
| c-LEcta–Capricorn Venture Partners: investment, 201808 financing round incl new + lead investor Capricorn investing via CSCF NV + Quest for Growth |
2018-08-23 |
| c-LEcta–SEVERAL: investment, 201808 financing round €na with new investors Capricorn Venture Partners + bm|t |
2018-08-23 |
| c-LEcta–Thuringia (govt): investment, 201808 financing round incl new + co-investor bm|t via MFT Mittelstands-Fonds Thüringen |
2018-08-23 |
| Novaremed–SEVERAL: investment, 201804 financing round CHF4.44m to support phase 2b study of NRD.E1 in DNP |
2018-08-23 |
| Novaremed–SEVERAL: investment, 201808 financing round CHF6m to support phase 2b study of NRD.E1 in DNP |
2018-08-23 |
| Merck (DE)–GlucoMe: digital health, 201808– collab digital diabetes management project in Vietnam |
2018-08-22 |
| Novo Group–Evotec: drug discovery services, 201808– collab €na strategic alliance r+d small molecule drugs for diabetes + obesity Novo Nordisk |
2018-08-22 |
| SolasCure–BRAIN: investment, 201808 financing round Series A with participation of BRAIN at spin-off of SolasCure from BRAIN |
2018-08-22 |
| SolasCure–BRAIN: wound care product, 201808– license IP for Aurase enzyme + supply of enzymatic active ingredient by BRAIN to SolasCure |
2018-08-22 |
| SolasCure–SEVERAL: investment, 201808 financing round Series A with participation of BRAIN |
2018-08-22 |
| NuGen–Tecan: investment, 201808 acquisition $54.5m in cash by Tecan |
2018-08-16 |
| Oncologie–Mologen: lefitolimod, 201808–201811 term sheet for acquisition of ww rights to lefitolimod by Oncologie TERMINATED 11/18 |
2018-08-15 |
| Bayer–Haplogen: antiviral agents, 201808– collab €na developm candidates for pulmonary diseases incl COPD |
2018-08-14 |
| Artios Pharma–AbbVie: investment, 201808 financing round Series B totalling $84m incl existing + co-investor AbbVie Ventures |
2018-08-10 |
| Artios Pharma–Andera Partners: investment, 201808 financing round Series B totalling $84m (£65m) incl new + lead investors Andera Partners + LSP |
2018-08-10 |
| Artios Pharma–Arix Bioscience: investment, 201808 financing round Series B totalling $84m incl existing + co-investor Arix Bioscience |
2018-08-10 |
| Artios Pharma–IP Group: investment, 201808 financing round Series B totalling $84m incl existing + co-investor IP Group |
2018-08-10 |
| Artios Pharma–Life Sciences Partners: investment, 201808 financing round Series B totalling $84m incl new + lead investors Andera Partners + LSP |
2018-08-10 |
| Artios Pharma–Merck (DE): investment, 201808 financing round Series B totalling $84m incl existing + co-investor M Ventures |
2018-08-10 |
| Artios Pharma–Novartis: investment, 201808 financing round Series B totalling $84m incl new + co-investor Novartis Venture Fund |
2018-08-10 |
| Artios Pharma–Pfizer: investment, 201808 financing round Series B totalling $84m incl new + co-investor Pfizer Ventures |
2018-08-10 |
| Artios Pharma–SEVERAL: investment, 201808 financing round Series B $84m (£65m) led by new investors Andera Partners + LSP |
2018-08-10 |
| Artios Pharma–SV Health Investors: investment, 201808 financing round Series B totalling $84m incl existing + co-investor SV |
2018-08-10 |
| Akouos–Novartis: investment, 201808 financing round Series A totalling $50m incl new co-investor Novartis Venture Fund |
2018-08-07 |
| Akouos–SEVERAL: investment, 201808 financing round Series A $50m co-led by existing investors 5AM Ventures + NEA |
2018-08-07 |
| United Kingdom (govt)–Bruker: NMR technology, 201808 supply £20m NMR technology to 8 UK universities funded by EPSRC + BBSRC + MRC +NERC |
2018-08-06 |
| Univ Birmingham–Bruker: NMR spectrometer, 201808 supply 1GHz NMR spectrometer |
2018-08-06 |
| Univ Warwick–Bruker: NMR spectrometer, 201808 supply Avance 1.0 GHz solid-state NMR spectrometer |
2018-08-06 |
| Arsanis–Gates Foundation: grant, 201808 grant $1.1.m for preclinical development of ASN500 programme |
2018-08-01 |
| Miraca–Qiagen: molecular companion diagnostics, 201808– collab with SRL to introduce of CDx tests in Japan in line with respective drug approvals |
2018-08-01 |
| Bayer–Leo Pharma: investment, 201807–201907 acquisition of global prescription dermatology business of Bayer |
2018-07-31 |
| B&W Tek–Metrohm: investment, 201807 acquisition €na of B&W Tek LLC + several overseas subisidiaries |
2018-07-27 |
| Biocrates–MC Services: public relations, 201807 service existent by MC Services |
2018-07-25 |
| Nabriva–SEVERAL: investment, 201807 public offering $50m net $46.1m with 18.2m ordinary shares at $2.75/share |
2018-07-25 |
| Innovative Medicines Initiative–Agena Bioscience: MassARRAY Technology, 201807– collab use of MassArray system in CANCER-ID Consortium |
2018-07-24 |
| Zavante Therapeutics–Nabriva: investment, 201807 acquisition upfront 8.2m Nabriva ordinary shares (=19.9% shareholding) + $97.5m milestones |
2018-07-24 |
| SHS–SEVERAL: investment, 201807 first closing €90m of SHS V fund with target size of €150m |
2018-07-20 |
| Novartis–MorphoSys: therapeutic antibody, 201807– license excl ww to MOR106 from MOR+GLPG €95m upfront + €850m milestones + royalties + funding |
2018-07-19 |
| Adocia–MC Services: public relations, 201807 service existent PR Europe by MC Services |
2018-07-18 |
| Agilent–AMETEK: FTIR analyzer, 201807 collab developm + manufacturing Miniscan IR LOG FTIR analyzer for in-field oil/grease analysis |
2018-07-18 |
| Beiersdorf–S-Biomedic: skin microbiomics, 201807– collaboration |
2018-07-18 |
| DCPrime–Glycotope: cancer immunotherapy, 201807– license + collab agreement research new approaches to solid tumours |
2018-07-18 |
| S-Biomedic–Beiersdorf: investment, 201807 financing round Series A 1st closing totalling €2m incl lead investor Beiersdorf AG |
2018-07-18 |
| S-Biomedic–JnJ: investment, 201807 financing round Series A 1st closing totalling €2m incl co-investor JnJ Innovation JJDC |
2018-07-18 |
| S-Biomedic–SEVERAL: investment, 201807 financing round Series A 1st closing €2m led by Beiersdorf + incl investiere.ch + JnJ Innovation JJDC |
2018-07-18 |
| S-Biomedic–Verve Capital Partners: investment, 201807 financing round Series A 1st closing totalling €2m incl co-investor investiere.ch |
2018-07-18 |
| B Braun–CeGaT: personalised medicine, 201807 collab establishment of B Braun Precision Medicine Technology (Shanghai) Ltd |
2018-07-17 |
| CeGaT–B Braun: investment, 201807 existent 30% shareholding of B Braun in CeGaT |
2018-07-17 |
| Labfolder–NEC: information technology, 201807– collab €na combining Labfolder s/w with NEC hardware for scalable data storage solutions |
2018-07-17 |
| Mosa Meat–Bell Food: investment, 201807 financing round Series A totalling €7.5m incl co-lead investor Bell Food Group |
2018-07-17 |
| Mosa Meat–Glass Wall Syndicate: investment, 201807 financing round Series A totalling €7.5m incl co-investor Glass Wall Syndicate |
2018-07-17 |
| Mosa Meat–Merck (DE): investment, 201807 financing round Series A totalling €7.5m incl co-lead investor M Ventures |
2018-07-17 |
| Mosa Meat–SEVERAL: investment, 201807 financing round Series A €7.5m co-led by M Ventures + Bell Food Group |
2018-07-17 |
| Polares Medical–Decheng Capital: investment, 201807 financing round totalling $25m incl lead investor Decheng Capital |
2018-07-17 |
| Polares Medical–Earlybird: investment, 201807 financing round totalling $25m incl co-investor Earlybird Venture Capital Berlin |
2018-07-17 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo-2019.png){kind=logo}
1 2 3 ... 15 16 17 ... 29 30 31 
Date
![Picture [iito] No Content Marketing 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-no-content-marketing.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
